vs
Side-by-side financial comparison of Almonty Industries Inc. (ALM) and CollPlant Biotechnologies Ltd (CLGN). Click either name above to swap in a different company.
CollPlant Biotechnologies Ltd is the larger business by last-quarter revenue ($10.2M vs $6.3M, roughly 1.6× Almonty Industries Inc.). CollPlant Biotechnologies Ltd runs the higher net margin — 56.6% vs -86.1%, a 142.6% gap on every dollar of revenue.
Almonty Industries Inc. is an international mining company primarily engaged in the extraction and development of tungsten resources. The company operates in Spain, Portugal, and South Korea and is publicly traded on the Toronto Stock Exchange (TSX). The current Chief Executive Officer is Lewis Black.
CollPlant Biotechnologies Ltd is a regenerative medicine company focused on developing and commercializing advanced products using its proprietary plant-derived human collagen technology. Its core offerings cover wound care, soft tissue repair, and aesthetic medicine solutions, targeting key markets across North America, Europe, and Israel, serving healthcare providers in dermatology, orthopedics and cosmetic care segments.
ALM vs CLGN — Head-to-Head
Income Statement — Q3 FY2025 vs Q2 FY2023
| Metric | | |
|---|---|---|
| Revenue | $6.3M | $10.2M |
| Net Profit | $-5.4M | $5.8M |
| Gross Margin | — | 94.0% |
| Operating Margin | — | 55.7% |
| Net Margin | -86.1% | 56.6% |
| Revenue YoY | — | 15330.3% |
| Net Profit YoY | — | 234.5% |
| EPS (diluted) | — | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $6.3M | — | ||
| Q2 25 | $7.2M | — | ||
| Q2 23 | — | $10.2M |
| Q3 25 | $-5.4M | — | ||
| Q2 25 | $-58.2M | — | ||
| Q2 23 | — | $5.8M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q2 23 | — | 94.0% |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q2 23 | — | 55.7% |
| Q3 25 | -86.1% | — | ||
| Q2 25 | -809.4% | — | ||
| Q2 23 | — | 56.6% |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q2 23 | — | $0.49 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $22.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $36.0M |
| Total Assets | — | $41.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q2 23 | — | $22.3M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q2 23 | — | $36.0M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q2 23 | — | $41.6M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
